Nurix Therapeutics, Inc. (NRIX) has a negative trailing P/E of -5.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -17.21%.
Criteria proven by this page:
Overall SharesGrow Score: 58/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -32.5 | 0.00 | -8.31 | 8.18 | - |
| 2019 | -34.0 | 6.69 | -12.79 | 23.73 | - |
| 2020 | -15.4 | -0.04 | 2.30 | 37.49 | - |
| 2021 | -10.5 | 9.70 | 3.61 | 41.55 | - |
| 2022 | -3.3 | -0.09 | 1.98 | 15.59 | - |
| 2023 | -2.3 | 0.08 | 1.69 | 4.39 | - |
| 2024 | -7.7 | -0.88 | 2.82 | 27.21 | - |
| 2025 | -5.5 | -0.94 | 2.72 | 17.45 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-0.59 | $37.45M | $-9.43M | -25.2% |
| 2019 | $-0.56 | $31.12M | $-21.7M | -69.7% |
| 2020 | $-2.76 | $17.82M | $-43.24M | -242.7% |
| 2021 | $-2.73 | $29.75M | $-117.19M | -393.9% |
| 2022 | $-3.42 | $38.63M | $-166.05M | -429.9% |
| 2023 | $-2.65 | $76.99M | $-143.95M | -187% |
| 2024 | $-2.88 | $54.55M | $-193.57M | -354.9% |
| 2025 | $-3.05 | $83.98M | $-264.46M | -314.9% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.12 | $-3.84 – $-2.65 | $57.53M | $52.22M – $64.17M | 12 |
| 2027 | $-3.00 | $-3.47 – $-2.29 | $72.83M | $37.56M – $139.32M | 9 |
| 2028 | $-2.51 | $-3.48 – $-1.31 | $114.55M | $114.54M – $114.57M | 10 |
| 2029 | $-1.92 | $-3.52 – $-0.76 | $241.67M | $129.87M – $397M | 4 |
| 2030 | $-0.35 | $-0.65 – $-0.14 | $492.66M | $264.75M – $809.31M | 4 |
